IAAG
STLN

Innovative Asset Advisors Group’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Innovative Asset Advisors Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195K Sell
36,000
-11,250
-24% -$47.3K 0.09% 182
2026
Q1 		$145K Buy
+47,250
New +$145K 0.08% 165

Other funds holding STLN

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Innovative Asset Advisors Group's STLN Position: Q2 2026 in Review

Innovative Asset Advisors Group reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 24% in Q2 2026, selling an estimated $47.3K and leaving 36,000 shares worth $195K. The position accounts for 0.09% of the portfolio, ranked #182.

Innovative Asset Advisors Group first reported a position in STLN in Q1 2026 and has held it in 2 quarters since. 29 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Innovative Asset Advisors Group held 36,000 shares of Starling Oncology Institute, Inc. Common Stock worth $195K as of Q2 2026.
  • Innovative Asset Advisors Group sold 11,250 Starling Oncology Institute, Inc. Common Stock shares in Q2 2026, an estimated $47.3K.
  • Starling Oncology Institute, Inc. Common Stock made up 0.09% of Innovative Asset Advisors Group's portfolio in Q2 2026, its #182 holding.
  • Innovative Asset Advisors Group first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2026 and has held it in 2 quarters since.
  • 29 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on Innovative Asset Advisors Group's 13F filing for Q2 2026, filed 5 Aug 2026.